LifeMD (NASDAQ:LFMD) Price Target Cut to $6.00 by Analysts at Mizuho

LifeMD (NASDAQ:LFMD) had its price target decreased by Mizuho from $7.00 to $6.00 in a research report released on Friday,Benzinga reports. Mizuho currently has an outperform rating on the stock.

A number of other analysts have also weighed in on LFMD. B. Riley Financial initiated coverage on shares of LifeMD in a research note on Friday, September 11th. They issued a “buy” rating and a $8.00 price objective for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of LifeMD in a report on Monday, November 2nd. KeyCorp set a $5.00 target price on shares of LifeMD and gave the company an “overweight” rating in a research report on Friday, August 7th. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of LifeMD in a research report on Thursday, September 17th. Finally, BTIG Research reduced their price target on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.14.

LifeMD Stock Performance

NASDAQ LFMD traded up $0.54 on Friday, reaching $2.19. 6,142,984 shares of the stock traded hands, compared to its average volume of 944,039. The company has a fifty day moving average price of $2.60 and a 200-day moving average price of $3.57. The company has a market cap of $105.80 million, a price-to-earnings ratio of -36.58 and a beta of 2.19. LifeMD has a 12 month low of $1.60 and a 12 month high of $5.38.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. LifeMD had a negative return on equity of 139.69% and a negative net margin of 0.25%. The business had revenue of $44.63 million during the quarter, compared to analysts’ expectations of $48.84 million. As a group, research analysts anticipate that LifeMD will post -0.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP boosted its position in LifeMD by 45.1% during the third quarter. Marshall Wace LLP now owns 809,138 shares of the company’s stock valued at $2,347,000 after purchasing an additional 251,664 shares in the last quarter. Empowered Funds LLC purchased a new position in LifeMD in the third quarter valued at about $160,000. Cibc World Market Inc. raised its holdings in LifeMD by 112.3% in the third quarter. Cibc World Market Inc. now owns 63,700 shares of the company’s stock worth $185,000 after purchasing an additional 33,700 shares in the last quarter. Chapin Davis Inc. bought a new position in LifeMD in the third quarter worth about $29,000. Finally, State Street Corp lifted its position in shares of LifeMD by 22.6% during the second quarter. State Street Corp now owns 1,318,784 shares of the company’s stock valued at $5,447,000 after buying an additional 243,376 shares during the last quarter. 35.52% of the stock is owned by institutional investors.

More LifeMD News

Here’s some of the latest news about LFMD:

• Positive Sentiment: LifeMD reported a third-quarter loss of $0.11 per share, narrower than the expected $0.14 loss. Adjusted EBITDA also improved by about $3.1 million sequentially, to a loss of roughly $0.4 million, as the company reduced marketing and other non-clinical expenses. LifeMD Q3 2026 results
• Neutral Sentiment: Lake Street Capital lowered its price target from $5 to $3 but kept a Buy rating; Mizuho cut its target from $7 to $6 and maintained an Outperform rating. The retained positive ratings offer support, though both target reductions reflect more cautious expectations. Analyst rating and price target update
• Negative Sentiment: Revenue was $44.6 million, below analysts’ $48.8 million estimate. LifeMD also forecast fourth-quarter revenue of $46–$49 million, versus consensus of $61.4 million, and full-year 2026 revenue of $188–$191 million, versus $207.6 million expected. The shortfall in guidance may weigh on investor expectations for near-term growth. LifeMD Q3 2026 results and guidance

LifeMD Company Profile

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.